Evidence map›Paper›PMID 40852693›Full record

ArticleInternational journal of hematology-oncology and stem cell research2025

ESHAP versus IEV Chemotherapy for Relapsed or Refractory Hodgkin's and Non-Hodgkin's Lymphoma.

Mehdi Dehghani, Reza Vojdani, Abolfazl Khalafi-Nezhad, Mohammad Reza Ravanbod, Mani Ramzi, Shima Dehdashti, Erfan Taherifard, Nasrin Namdari

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of hematology-oncology and stem cell research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Mehdi DehghaniDepartment of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Reza VojdaniDepartment of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abolfazl Khalafi-NezhadDepartment of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Reza RavanbodDepartment of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
Mani RamziDepartment of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Shima DehdashtiDepartment of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.
Erfan TaherifardDepartment of Hematology and Medical Oncology, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Nasrin NamdariDepartment of Hematology and Medical Oncology, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ESHAPHodgkin's lymphoma and non-Hodgkin’s lymphomaIEV

Identifiers

PMID40852693
PMCPMC12368709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.